1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF
One older study from 2002 found that an emulsion containing 10% Argireline reduced wrinkle depth in women volunteers up to 30% after 30 days of treatment
2 The Medicare GLP-1 Bridge program runs from July 1, 2026 through December 31, 2027
KorpelaKFlintHJJohnstoneAMLappiJPoutanenKDewulfEet alGut microbiota signatures predict host and microbiota responses to dietary interventions in obese individuals
Both are once-weekly GLP-1 receptor agonists approved for type 2 diabetes, but they are different molecules with different efficacy and side effect profiles
(2004) Topical glyceryl trinitrate treatment of chronic noninsertional achilles tendinopathy